JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB109114

Anti-NAT1 antibody [EPR3221(2)]

Be the first to review this product! Submit a review

|

(10 Publications)

Rabbit Recombinant Monoclonal NAT1 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 10 publications.

View Alternative Names

AAC1, NAT1, Arylamine N-acetyltransferase 1, Arylamide acetylase 1, Monomorphic arylamine N-acetyltransferase, N-acetyltransferase type 1, MNAT, NAT-1

3 Images
Flow Cytometry (Intracellular) - Anti-NAT1 antibody [EPR3221(2)] (AB109114)
  • Flow Cyt (Intra)

Lab

Flow Cytometry (Intracellular) - Anti-NAT1 antibody [EPR3221(2)] (AB109114)

Flow Cytometry analysis of LNCaP (Human prostate carcinoma epithelial cell) cells labeling NAT1 with purified ab109114 at 1/100 dilution (10 μg/mL) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).

Immunocytochemistry/ Immunofluorescence - Anti-NAT1 antibody [EPR3221(2)] (AB109114)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-NAT1 antibody [EPR3221(2)] (AB109114)

Immunofluorescent staining of LN-CAP cells using anti-NAT1 at 1/100 (ab109114).

Western blot - Anti-NAT1 antibody [EPR3221(2)] (AB109114)
  • WB

Unknown

Western blot - Anti-NAT1 antibody [EPR3221(2)] (AB109114)

All lanes:

Western blot - Anti-NAT1 antibody [EPR3221(2)] (ab109114) at 1/1000 dilution

Lane 1:

U937 cell lysate at 10 µg

Lane 2:

Fetal liver cell lysate at 10 µg

Lane 3:

LnCaP cell lysate at 10 µg

Lane 4:

Human bladder cell lysate at 10 µg

Lane 5:

HT-1376 cell lysate at 10 µg

Predicted band size: 34 kDa

false

  • Carrier free

    Anti-NAT1 antibody [EPR3221(2)] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR3221(2)

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

Flow Cyt (Intra), WB, ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Alternative Products

Primary Antibodies

AB175088

Anti-NAT1 antibody

Western blot - Anti-NAT1 antibody (AB175088)

  • 0
  • 0

Complementary Products

Secondary Antibodies

AB150113

Goat Anti-Mouse IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) (AB150113)

  • 5
  • 15
Primary Antibodies

AB134045

Anti-CD63 antibody [EPR5702] - Late Endosome Marker

RabMAb|Recombinant|KO Validated|Lab Essentials|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CD63 antibody [EPR5702] - Late Endosome Marker (AB134045)

  • 3
  • 6
Primary Antibodies

AB125011

Anti-TSG101 antibody [EPR7130(B)]

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry - Anti-TSG101 antibody [EPR7130(B)] (AB125011)

  • 4
  • 10
Primary Antibodies

AB109012

Anti-SQSTM1 / p62 antibody [EPR4844] - Autophagosome Marker

KO Validated|RabMAb|Recombinant|Lab Essentials

Western blot - Anti-SQSTM1 / p62 antibody [EPR4844] - Autophagosome Marker (AB109012)

  • 5
  • 15
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100 - 1/250", "ICCIF-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/100", "FlowCytIntra-species-notes": "<p><a href='/en-us/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>" } } }
style
left-column

Product details

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.05% Sodium azide Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Storage information
Stable for 12 months at -20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

NAT1 also known as arylamine N-acetyltransferase 1 serves as an important enzyme in acetylation reactions. This enzyme with a molecular mass of approximately 33 kDa catalyzes the transfer of acetyl groups to arylamines and other substrates such as hydrazines. By doing so NAT1 influences xenobiotic metabolism. The enzyme is expressed in various tissues most notably in the liver intestine and lung which aligns with its role in detoxifying and metabolizing drugs and carcinogens.
Biological function summary

NAT1 plays a significant role in detoxifying environmental toxins and carcinogens. The enzyme's activity contributes to the acetylation a phase II metabolic reaction which often converts lipophilic substrates into more hydrophilic products for excretion. NAT1 stands independently and does not form part of a larger complex. It shares functional similarities with other N-acetyltransferases but its substrate specificity can differ which influences its distinct biological role.

Pathways

NAT1 is intricately involved in metabolic and detoxification pathways. It participates in the biotransformation of various drugs and environmental carcinogens making it important for xenobiotic metabolism. NAT1 often interacts with cytochrome P450 enzymes during these processes which also contribute to the initial phase I oxidation reactions. The interplay between NAT1 and these detoxification pathways highlights the enzyme's contribution to reducing potential toxicities.

NAT1 has associations with both cancer and hypersensitivity to certain drugs. Variations in NAT1 activity due to genetic polymorphisms can influence individual susceptibility to cancers particularly bladder cancer linked to arylamine exposure. Additionally its interaction with cytochrome P450 enzymes may also impact drug metabolism potentially leading to adverse drug reactions. Understanding NAT1 and its interactions help assess risks related to these diseases.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.
See full target information NAT1
style
left-column

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 14:20817 PubMed39242625

2024

LSD1 inhibits the invasion and migration of breast cancer through exosomes.

Applications

Unspecified application

Species

Unspecified reactive species

Nan Zhang,Zhongyu Chen,Benkai Xin,Yueru Shi,Yutong Yao,Jingtong Yang,Xiaoyu Wang,Xin Hu

Biochemistry and biophysics reports 38:101716 PubMed38737726

2024

Function and expression of N-acetyltransferases 1 and 2 are altered in lymphocytes in type 2 diabetes and obesity.

Applications

Unspecified application

Species

Unspecified reactive species

Víctor Alejandro Paz-Rodríguez,Diana Judith Herrera-Vargas,Eneida Turiján-Espinoza,Miguel Ernesto Martínez-Leija,Emmanuel Rivera-López,Oswaldo Hernández-González,Daniel Zavala-Reyes,Mariana Haydee García-Hernández,Juan Manuel Vargas-Morales,Rosa Del Carmen Milán-Segovia,Diana Patricia Portales-Pérez

Breast cancer research and treatment 195:223-236 PubMed35918499

2022

Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Courtney E McAleese,Neville J Butcher,Rodney F Minchin

Toxicology and applied pharmacology 449:116095 PubMed35662664

2022

Hexavalent chromium increases the metabolism and genotoxicity of aromatic amine carcinogens 4-aminobiphenyl and β-naphthylamine in immortalized human lung epithelial cells.

Applications

Unspecified application

Species

Unspecified reactive species

James T F Wise,Raúl A Salazar-González,Kennedy M Walls,Mark A Doll,Mariam R Habil,David W Hein

Toxicology and applied pharmacology 442:115993 PubMed35353990

2022

Expression of arylamine N-acetyltransferase 2 activity in immortalized human bronchial epithelial cells.

Applications

Unspecified application

Species

Unspecified reactive species

James T F Wise,Raúl A Salazar-González,Mariam R Habil,Mark A Doll,David W Hein

Frontiers in pharmacology 13:797469 PubMed35153780

2022

Arylamine -Acetyltransferase 1 Activity is Regulated by the Protein Acetylation Status.

Applications

Unspecified application

Species

Unspecified reactive species

Raúl A Salazar-González,Mark A Doll,David W Hein

Experimental and therapeutic medicine 23:12 PubMed34815764

2021

Long non-coding RNA H19 mediates N-acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Hong Sun,Guo Wang,Jiaqin Cai,Xiaoxia Wei,Ying Zeng,Yan Peng,Jie Zhuang

Scientific reports 10:7566 PubMed32372066

2020

Human arylamine N-acetyltransferase 2 genotype-dependent protein expression in cryopreserved human hepatocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Raúl A Salazar-González,Mark A Doll,David W Hein

Journal of oncology 2019:3860426 PubMed31531019

2019

-Acetyltransferase 1 Knockout Elevates Acetyl Coenzyme A Levels and Reduces Anchorage-Independent Growth in Human Breast Cancer Cell Lines.

Applications

Unspecified application

Species

Unspecified reactive species

Marcus W Stepp,Raúl A Salazar-González,Kyung U Hong,Mark A Doll,David W Hein

Leukemia & lymphoma 59:1968-1975 PubMed29214875

2017

Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.

Applications

Unspecified application

Species

Unspecified reactive species

Oswaldo Hernández-González,Juan José Ortiz-Zamudio,Cristian Jazmín Rodríguez-Pinal,Ildemar Alvarado-Morales,Verónica Del Carmen Martínez-Jiménez,Raúl Alejandro Salazar-González,Lourdes Cecilia Correa-González,Rocío Gómez,Diana Patricia Portales-Pérez,Rosa Del Carmen Milán-Segovia
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com